The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Development of Recombinant Vesicular Stomatitis Viruses That Exploit Defects in Host Defense To Augment Specific Oncolytic Activity
Open accessAbstract
Vesicular stomatitis virus (VSV) is a negative-stranded RNA virus normally sensitive to the antiviral actions of alpha/beta interferon (IFN-α/β). Recently, we reported that VSV replicates to high levels in many transformed cells due, in part, to susceptible cells harboring defects in the IFN system. These observations were exploited to demonstrate that VSV can be used as a viral oncolytic agent to eradicate malignant cells in vivo while leaving normal tissue relatively unaffected. To attempt to improve the specificity and efficacy of this system as a potential tool in gene therapy and against malignant disease, we have genetically engineered VSV that expresses the murine IFN-β gene. The resultant virus (VSV-IFNβ) was successfully propagated in cells not receptive to murine IFN-α/β and expressed high levels of functional heterologous IFN-β. In normal murine embryonic fibroblasts (MEFs), the growth of VSV-IFNβ was greatly reduced and diminished cytopathic effect was observed due to the production of recombinant IFN-β, which by functioning in a manner involving autocrine and paracrine mechanisms induced an antiviral effect, preventing virus growth. However, VSV-IFNβ grew to high levels and induced the rapid apoptosis of transformed cells due to defective IFN pathways being prevalent and thus unable to initiate proficient IFN-mediated host defense. Importantly, VSV expressing the human IFN-β gene (VSV-hIFNβ) behaved comparably and, while nonlytic to normal human cells, readily killed their malignant counterparts. Similar to our in vitro observations, following intravenous and intranasal inoculation in mice, recombinant VSV (rVSV)-IFNβ was also significantly attenuated compared to wild-type VSV or rVSV expressing green fluorescent protein. However, VSV-IFNβ retained propitious oncolytic activity against metastatic lung disease in immunocompetent animals and was able to generate robust antitumor T-cell responses. Our data indicate that rVSV designed to exploit defects in mechanisms of host defense can provide the basis for new generations of effective, specific, and safer viral vectors for the treatment of malignant and other disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeted mutation of the DNA methyltransferase gene results in embryonic lethality
Li, E., Bestor, T. H., & Jaenisch, R. (1992) · Cell · doi:10.1016/0092-8674(92)90611-f · Cited by 3,984
Virus interference. I. the interferon
Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451
The Stat family in cytokine signaling
Ihle, J. N. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00199-x · Cited by 713
Cited by
LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus
Finkelshtein, D., Werman, A., Novick, D., Barak, S., & Rubinstein, M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1214441110 · Cited by 656
Vesicular stomatitis virus: re-inventing the bullet
Lichty, B. D., Power, A. T., Stojdl, D. F., & Bell, J. C. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.03.003 · Cited by 319
Oncolytic Immunovirotherapy for Melanoma Using Vesicular Stomatitis Virus
Diaz, R. M., Galivo, F., Kottke, T., Wongthida, P., Qiao, J., Thompson, J., Valdes, M., Barber, G., & Vile, R. G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3974 · Cited by 264
Self-citationDirect priming of antiviral CD8+ T cells in the peripheral interfollicular region of lymph nodes
Hickman, H. D., Takeda, K., Skon, C. N., Murray, F. R., Hensley, S. E., Loomis, J., Barber, G. N., Bennink, J. R., & Yewdell, J. W. (2008) · Nature Immunology · doi:10.1038/ni1557 · Cited by 256
Self-citationTrial watch: Oncolytic viruses for cancer therapy
Vacchelli, E., Eggermont, A., Sautès-Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24612 · Cited by 255
Metadata
- Authors
- Obuchi, M., Fernandez, M., & Barber, G. N.
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2003-08-15
- Volume
- 77
- Issue
- 16
- Pages
- 8843-8856
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- OpenAlex
- W2124160523
- Cited by
- 215
- References
- 3
- FWCI
- 5.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of Recombinant Vesicular Stomatitis Viruses That Exploit Defects in Host Defense To Augment Specific Oncolytic Activity. https://app.cochat.ai/papers/10.1128/jvi.77.16.8843-8856.2003
- The paper
- Obuchi, M., Fernandez, M., & Barber, G. N. (2003). Development of Recombinant Vesicular Stomatitis Viruses That Exploit Defects in Host Defense To Augment Specific Oncolytic Activity. Journal of Virology. https://doi.org/10.1128/jvi.77.16.8843-8856.2003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.